Biotech Transformation NetworkRecently, Jiangsu Trulive Medtech Co., Ltd. (hereinafter referred to as "Trulive"), a rare platform-type interventional innovation enterprise in China that focuses on "blood flow management," officially announced the completion of an over 100-million-yuan Series C financing round. Trulive successfully secures a financing round every year, with strong and sustained confidence from the capital market. This round of financing was jointly completed by multiple institutions, including Oriental Fortune, Guoyuan Equity, Xiamen Industrial Investment/Venture Capital, Xiamen Gold Innovation, Bozheng Capital, Siming Technology Innovation, and existing shareholder Life Tree Capital.
This financing round is one of the multiple significant capital initiatives completed by Trulive within a few years. It not only signifies the capital market's deep recognition of Trulive’s platform-based strategy and commercialization prospects but also reflects the potential of China's high-end medical device enterprises.A New Paradigm for Technological Breakthrough and Ecosystem Construction in the Field of Cardiovascular Interventions.Founder and Chairman of TruliveWen Jing, graduated from the Mechatronics Engineering program at Shanghai Jiao Tong University with a master's degree. He has over 10 years of management experience in the cardiovascular industry and is one of the first generation of "valve professionals" in China, personally driving the first wave of valve development in the country. In addition, Wen Jing was selected for Fortune China's 2023 list of 40 business elites under the age of 40 and was named in the "2025 Hurun U40 China Entrepreneurial Pioneer" list in November 2025.
Founder of Trulive, Wen Jing
Since its establishment in 2019, Trulive has focused on the field of cardiovascular diseases, which have extremely high mortality and disability rates, and where the market for domestically produced solutions remains空白. Its operations comprehensively cover multiple interventional treatment areas such as heart valves, peripherals, and coronary arteries. It is a platform enterprise that has taken the lead in providing a one-stop innovative solution for blood flow management on a global scale.Especially in the field of structural heart disease, where clinical needs are urgent and the competitive landscape has yet to solidify—such as in the mitral and tricuspid valve sectors—Trulive has built a differentiated advantage. It innovatively proposes a "1+1>2" synergistic development strategy by simultaneously deploying product pipelines for both mitral and tricuspid valves, covering both repair and replacement technologies. This has formed a rare full-scenario solution capability in China, along with a leading toolbox product system domestically. It meets the diverse treatment needs of patients with different conditions and anatomical structures, effectively filling the gap in high-end medical devices for mitral and tricuspid valve interventional treatments in China.Central-med Club is established byShang Ji TransformationInitiated, and jointlyMultiple listed companies、Frontline Investment InstitutionsThe biomedicine industry service platform, established in accordance with the "14th Five-Year Plan for Bioeconomy Development," follows the trend of accelerating global biotechnology advancements. It promotes the rapid application of biotechnology innovation and industrialization through diversified services, facilitates the transfer and transformation of scientific and technological achievements, supports the rapid growth of enterprises, serves the specialized, refined, distinctive, and innovative development of enterprises, and assists such enterprises in going public, aiming to create the most innovative and dynamic "Empowerment Platform for High-Quality Enterprise Development”。
![]()
![]()
Welcome to scan the code to join Trulive Academy
![]()
![]()
